CanSino’s single dose Covid-19 booster vaccination is approved by MoH.
Convidecia, a single-dose vaccine from CanSino, has received approval from Malaysia’s Health Ministry (MOH) for use as a heterologous booster with all Covid-19 main vaccines.
In a statement released today, Solution Group Bhd, the Asean manufacturing partner of CanSino Biologics Inc, stated the vaccine was approved for adults 18 years of age and older, irrespective of the type of vaccine they had previously received during their Covid-19 vaccination.
The statement added, “It is also the first and only Covid-19 vaccine from China to be included in the heterologous vaccination programme in Malaysia that can be administered as a mix-and-match with both Pfizer-BioNTech and AstraZeneca Covid-19 vaccines. Convidecia will be administered as a booster dose after at least three months have passed since recipients received their second dose of their primary vaccination.
In the same statement, Datuk Mohd Nazlee Kamal, the deputy group managing director of SGB, noted that studies conducted recently in China demonstrated that using Convidecia as a heterologous booster, either through intramuscular injection or using the inhaled version, increased the production of neutralising antibody responses.
The Events Supposedly Attributable to Vaccination or Immunisation (ESAVI) Report, recently released by the Mexican health authorities, further supported the vaccine’s safety profile in actual use.
